Clinical trials: Seizure
Hearing Loss, Hearing Impairment
Performance and Effectiveness of a Self-fitting Over-the-counter Hearing Aid
Hearing loss significantly affects quality of life, with sensorineural hearing loss being the most common type among adults. Hearing aids are a proven intervention, yet barriers like access and affordability limit their adoption…
- Trial name
- Lexie (NCT06942325)
- Testing
- OTC self-fitting hearing aid, Prescription hearing aid
- Sponsor
- HearX SA
Epilepsy
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.
- Trial name
- NCT00504881
- Testing
- Brivaracetam
- Where
- 61 sites in Austria, Belgium and 13 more
- Volunteers
- 480 people
- Sponsor
- UCB Pharma SA
Status Epilepticus
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
This study is designed to optimize the dosing regimen and evaluate the preliminary safety and efficacy of Intravenous (IV) ganaxolone as adjuvant therapy for participants with ESE receiving initial IV antiepileptic drug (AED)…
- Trial name
- NCT05757544
- Testing
- IV Ganaxolone
- Sponsor
- Marinus Pharmaceuticals
Epilepsy
Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
- Trial name
- NCT01529034
- Testing
- USL261
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 175 people
- Sponsor
- UCB Biopharma S.P.R.L.
Focal Epilepsy, Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in…
- Conditions
- Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
- Trial name
- NCT07219407
- Testing
- RAP-219
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Epilepsy
RNS® System Feasibility Study
The RNS® System is intended to treat patients with medically refractory (hard to treat) epilepsy. The RNS® System Feasibility study is designed to demonstrate safety and evidence of effectiveness of the RNS® System to support the…
- Trial name
- NCT00079781
- Testing
- RNS® System implantation, RNS® System responsive stimulation
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- NeuroPace
Focal Onset Seizure
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age).
- Trial name
- NCT06453213
- Testing
- Cenobamate
- Where
- 19 sites in United States
- Volunteers
- 49 people
- Sponsor
- SK Life Science, Inc.
Sensorineural Hearing Loss, Bilateral, Bilateral Hearing Loss
Comparison in New Cochlear Implanted Subjects of a Tonotopy-based Bimodal Fitting and a Conventional Fitting
Main objective: For a bimodal fitting (hearing aid (HA) + cochlear implant (CI)): Comparison of a tonotopy based fitting strategy (TFS4) to a default fitting strategy (FS4) for the speech recognition in noise.
- Trial name
- NCT05955469
- Testing
- FS4 then TFS4 (cochlear implant), TFS4 then FS4 (cochlear implant)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- MED-EL Elektromedizinische Geräte GmbH
Epilepsy
RNS® System Pivotal Study
The RNS® System Pivotal study is designed to assess safety and demonstrate that the RNS® System is effective as an adjunctive (add-on) therapy in reducing the frequency of seizures in individuals 18 years of age or older with…
- Trial name
- NCT00264810
- Testing
- RNS® System implantation, RNS® System responsive stimulation
- Where
- 32 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroPace
Hearing Loss, Ear Diseases
Baseline Performance and Fitting Parameters for Sonova Products
The purpose of this study is to assess the effectiveness and optimization of various FDA approved products.
- Conditions
- Hearing Loss, Ear Diseases, Hearing Disorders, Otolaryngological Disease
- Trial name
- NCT05859568
- Testing
- Pinna-located microphone, Pinna-simulated microphone algorithm
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Advanced Bionics
Epilepsy
Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures
The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.
- Trial name
- NCT00515619
- Testing
- Lacosamide
- Where
- 54 sites in Australia, Croatia and 11 more
- Volunteers
- 376 people
- Sponsor
- UCB Pharma
Epilepsy, Complex Partial Seizures
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
The purpose of this open-label extension study is to demonstrate that RWJ-333369 is safe as long-term add-on treatment of partial onset seizures.
- Conditions
- Epilepsy, Complex Partial Seizures, Epilepsy, Complex Partial, Epilepsies, Partial
- Trial name
- NCT00991757
- Testing
- carisbamate
- Volunteers
- 991 people
- Sponsor
- SK Life Science, Inc.
Altered Mental Status
Putting Electroencephalography (EEG) in the Emergency Department
The proposed study aims to test the impact of microEEG on clinical management (diagnosis and treatment) of emergency department patients with Altered Mental Status (AMS).
- Trial name
- NCT01671475
- Testing
- microEEG (Bio-Signal microEEG)
- Where
- 2 sites in United States
- Volunteers
- 149 people
- Sponsor
- Bio-Signal Group Corp.
Seizures, Motor, Seizures
Study to Validate Novel Seizure-Detection Algorithm
The specificity and sensitivity of a novel seizure-detection mobile software application with a generalized tonic/clonic seizure detection algorithm (Motor Seizure Detection Algorithm [mSDA]) installed on a wearable device to be…
- Conditions
- Seizures, Motor, Seizures, Seizure Disorder, Epilepsy
- Trial name
- NCT04291716
- Testing
- Motor Seizure Detection Algorithm (mSDA)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Overwatch Digital Health
Epilepsy, Lennox-Gastaut Syndrome
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
- Trial name
- GWPCARE4 (NCT02224690)
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 24 sites in United States, Netherlands and 1 more
- Volunteers
- 171 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy, Idiopathic Generalized Epilepsy
RNS System NAUTILUS Study
To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant…
- Conditions
- Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
- Trial name
- NAUTILUS (NCT05147571)
- Testing
- Responsive stimulation
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroPace
Epilepsy, Seizures, Epileptic
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
- Trial name
- NCT05518578
- Testing
- SPN-817
- Where
- 10 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Focal Seizure
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
- Trial name
- POWER1 (NCT06999902)
- Testing
- 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
- Where
- 69 sites in United States, Brazil and 5 more
- Volunteers
- 255 people
- Sponsor
- Praxis Precision Medicines
Drug Resistant Epilepsy, Epilepsy
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in…
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure
- Trial name
- NCT06388707
- Testing
- NaviFUS System
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NaviFUS Corporation
Partial Seizure Disorder, Epilepsy
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
- Conditions
- Partial Seizure Disorder, Epilepsy, Seizures
- Trial name
- NCT00113815
- Testing
- topiramate
- Where
- 94 sites in United States, Argentina and 21 more
- Volunteers
- 118 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.